{
  "topics": [
    { "id": "lymphoma", "name": "Canine/Feline Lymphoma", "mastery": 35 },
    { "id": "mast-cell", "name": "Mast Cell Tumors", "mastery": 50 },
    { "id": "hemangiosarcoma", "name": "Hemangiosarcoma", "mastery": 25 },
    { "id": "osteosarcoma", "name": "Osteosarcoma", "mastery": 40 },
    { "id": "chemotherapy-safety", "name": "Chemotherapy Safety", "mastery": 65 }
  ],
  "quizBank": [
    {
      "id": "q1",
      "topicId": "lymphoma",
      "type": "mcq",
      "question": "Which immunophenotype generally has a better prognosis in canine multicentric lymphoma?",
      "options": ["T-cell", "B-cell", "Null-cell", "Plasma-cell"],
      "answer": "B-cell",
      "explanation": "B-cell lymphoma often has better response duration and overall prognosis than T-cell in many cohorts."
    },
    {
      "id": "q2",
      "topicId": "mast-cell",
      "type": "short",
      "question": "Name two negative prognostic indicators for canine mast cell tumors.",
      "answerKeywords": ["high grade", "high mitotic index", "metastasis", "subcutaneous high grade", "KIT mutation"],
      "explanation": "Grade, mitotic index, and metastatic disease are key prognostic drivers."
    }
  ],
  "cases": [
    {
      "id": "case1",
      "title": "Canine multicentric lymphoma - initial workup",
      "template": [
        "Signalment and presenting complaint",
        "Staging tests performed",
        "Substage and immunophenotype",
        "Initial protocol and owner goals",
        "Monitoring and toxicity plan"
      ]
    },
    {
      "id": "case2",
      "title": "Feline injection-site sarcoma planning",
      "template": [
        "Tumor mapping and imaging",
        "Surgical margin strategy",
        "Adjuvant radiation/chemo considerations",
        "Follow-up intervals and recurrence risk discussion"
      ]
    }
  ]
}
